Daratumumab-Based Second Line Therapy Improves Outcomes After VRD Induction, Upfront Autologous Transplant, and Lenalidomide Maintenance
Multiple myeloma patients receiving daratumumab-based treatment after relapse lived roughly five times longer without progression than those on older drug combinations.
In this MD Anderson retrospective cohort of 146 multiple myeloma patients relapsing after VRD induction, autoHCT, and lenalidomide maintenance, daratumumab-based second-line therapy produced a median PFS2 of ~60 months, nearly 5 times longer than IMiD/PI-based doublets or triplets. These real-world data support daratumumab-based regimens as preferred second-line therapy in this well-defined patient population.
What the study was
- Study design
- Retrospective single-center cohort study
- Population
- Multiple myeloma patients post-VRD induction, autoHCT, lenalidomide maintenance; MD Anderson Cancer Center
- Sample size
- 146
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Clinical Lymphoma, Myeloma & Leukemia
Why it surfaced
Real-world data confirming daratumumab superiority in lenalidomide-refractory MM post-transplant; near-term practice-confirmatory; retrospective single-center design and modest n=146 limit generalizability.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.